Thyroid cancer is the most common malignant tumor of the endocrine system, and its incidence has increased significantly in the past 40 years. Studies have shown that glycogen metabolism plays an oncogenic role in multiple tumor types. Glycogen genes and enzymes may be expressed in normal thyroid and thyroid cancer cells based on RNA-sequencing data of anaplastic thyroid cancer (ATC) cells. Therefore, glycans and cancer biomarkers based on aberrantly glycosylated proteins have gained increasing recognition. Most tumor biomarkers currently used clinically are glycoproteins. Aberrant glycosylation has been identified as a hallmark of cancer. Meanwhile, it offered a new view of cancer research involving underlying mechanisms of investigation and clinical translation and application.
Fig.1 Glycolysis and glycogen metabolism. (Davidson & Carr, 2021)
With constant collaboration and innovation over the years, CD BioGlyco is a professional cancer glycogene discovery servicer with strong scientific research capabilities and an advanced technology platform. We formulate different programs to meet the needs of clients to ensure that we provide the best service for different projects.
Fig.2 Glycogene discovery in thyroid cancer. (CD BioGlyco)
CD BioGlyco is committed to providing first-class Cancer Glycogene Discovery Services. We have professional team management and a high-quality R&D team. Besides cancer glycogene discovery, we also provide Glycogene Editing Services and Glycogene Delivery Services. If you are interested in our service, please feel free to contact us at any time.